MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Visiongain
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

World Biomarkers Market will Reach $15.29 Billion in 2012 New Visiongain Report Predicts - A new report by visiongain predicts that the global market for biomarkers will be worth $15.29 billion in 2012 - Visiongain.com
World Biomarkers Market will Reach $15.29 Billion in 2012 New Visiongain Report Predicts

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/07/24 - A new report by visiongain predicts that the global market for biomarkers will be worth $15.29 billion in 2012 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Between 2011 and 2016, the world market will grow with a CAGR of 11.0%. Increased use of biomarkers in drug development will drive growth. Those findings appear in Biomarkers: Technological and Commercial Outlook 2012-2022, published in July 2012.

Visiongain forecasts that biomarker diagnostics will be the biggest sector of the market in 2022, overtaking biomarker development and technologies, in terms of revenue, in 2017. In 2011, biomarker diagnostics achieved revenue of $5.55bn. Increased demand for companion diagnostics and non-invasive tests will drive growth in this sector. Leading market players include pharmaceutical companies co-developing drugs and diagnostics - such as Roche Diagnostics - and leading diagnostic developers, including Genomic Health and Myriad Genetics.

Richard Lang, a pharmaceutical industry analyst in visiongain, said: “Doctors, patients and healthcare payers are demanding new tools for early and accurate diagnosis of disease. Biomarkers represent a strong opportunity for the development of non-invasive diagnostic and prognostic tests. Identifying the most suitable treatment for a patient will cut healthcare spending and help avoid potential adverse events. Other drivers for growth in the biomarkers market in coming years will be the increased validation of biomarkers. Many markers were discovered in the past decade but relatively few have been commercialised.”

This study forecasts the future of three key disciplines in the biomarkers market: genomics, proteomics and bioinformatics. In 2011, genomics accounted for the largest share of biomarker research, driven by initiatives such as The Cancer Genome Atlas and the International Cancer Genome Consortium. In the coming 10 years newer disciplines for biomarker discovery, including metabolomics and glycomics, will receive greater attention.

Visiongain’s report also provides revenue forecasts for leading national markets for biomarker diagnostics and technologies. In 2011, the US was the leading market for biomarkers, accounting for over 60% of global revenues in that year. Strong growth is forecast for that national market, driven by the approval of diagnostics and the integration of biomarkers into drug development. Many of the market leading companies are based in the US. Increasing availability of biomarker technologies in China will drive market growth there. In 2016, that national market will be valued at $0.66bn.

Biomarkers: Technological and Commercial Outlook 2012-2022 assesses the market in terms of sector, discipline, therapeutic area and country. The study adds to visiongain’s portfolio of analytical reports covering the pharmaceutical and healthcare technology markets. Visiongain is a business information provider based in London, UK.

For sample pages and further information concerning the visiongain report Biomarkers: Technological and Commercial Outlook 2012-2022 please visit the website.

About Visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


World Biomarkers Market will Reach $15.29 Billion in 2012 New Visiongain Report Predicts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)